1 Eidgenössische Kommission für Sexuelle Gesundheit. Postexpositionelle Prophylaxe (PEP) von HIV ausserhalb des Medizinalbereichs. Schweiz Med Forum. 2014;14:151–3.
2 US Food and Drug Adminstration FDA. Press Announcements – FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at:
https://wayback.archive-it.org/7993/20170112032741/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm.
3 World Health Organization. WHO | Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. WHO 2014; Available at:
www.who.int/hiv/pub/guidelines/keypopulations/en/.
4 US Public Health Service. Pre-exposure prophylaxis for the prevention of HIV infection in the United States – 2014. A clinical practice guideline. Available at:
www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Accessed 17 August 2015.
5 European Medicines Agency EMA. First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU. 2016. Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002578.jsp&mid=WC0b01ac058004d5c1. Accessed 15 September 2016.
6 Eidgenössische Kommission für Sexuelle Gesundheit. Empfehlungen der Eidgenössischen Kommission für sexuelle Gesundheit (EKSG) zur HIV Prä- Expositionsprophylaxe (PrEP) in der Schweiz. BAG Bulletin. 2016; :77–9.
7 Mugwanya K, Baeten J, Celum C, et al. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. J Infect Dis. 2016; :jiw125.
8 Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV-infizierte Menschen ohne andere STD sind unter wirksamer antiretroviraler Therapie sexuell nicht infektiös. Schweizerische Arztezeitung. 2008:165–9.
9 Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973–83.
10 Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.
11 McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015;387:57–60.
12 Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016;375:830–9.
13 Molina J-M, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237–46.
14 Grant RM, Koester KA. What people want from sex and preexposure prophylaxis. current opinion in HIV and AIDS. 2016;11:3–9.
15 The Lancet Hiv. Time for NHS England to accept responsibility for PrEP. Lancet HIV. 2016;3:e397.